Key Developments: Thoratec Corp (THOR.OQ)

THOR.OQ on NASDAQ Stock Exchange Global Select Market

32.81USD
24 Dec 2014
Price Change (% chg)

$0.74 (+2.31%)
Prev Close
$32.07
Open
$32.09
Day's High
$33.04
Day's Low
$32.09
Volume
81,339
Avg. Vol
273,985
52-wk High
$38.68
52-wk Low
$22.50

Search Stocks

Latest Key Developments (Source: Significant Developments)

Thoratec Corp lowers FY 2014 guidance
Wednesday, 5 Nov 2014 04:05pm EST 

Thoratec Corp:Adjusts FY 2014 guidance for revenues to a range of $450 million to $460 million and for net income per diluted share to a range of $0.70 to $0.80 on a GAAP basis and $1.20 to $1.30 on a non-GAAP basis.FY 2014 revenue of $462 million and EPS of $1.32 - Thomson Reuters I/B/E/S.  Full Article

Thoratec Corp appoints new president and chief executive officer
Monday, 22 Sep 2014 07:30am EDT 

Thoratec Corp:Says D. Keith Grossman has been appointed President and Chief Executive Officer, effective immediately.Grossman succeeds Gary F. Burbach, who has stepped down from his executive and board roles but will remain as an advisor to the company through the first quarter of 2016.  Full Article

Thoratec Corp lowers FY 2014 guidance
Wednesday, 6 Aug 2014 04:03pm EDT 

Thoratec Corp:Expects FY 2014 revenue guidance to a range of $455 to $470 mln.Expects FY 2014 net income per diluted share to $0.80 to $0.90 on a GAAP basis and $1.25 to $1.35 on a non-GAAP basis.FY 2014 revenue of $523 million and EPS of $1.75 - Thomson Reuters I/B/E/S.  Full Article

Thoratec Corp announces start of the HeartMate PHP CE Mark Trial
Wednesday, 6 Aug 2014 04:02pm EDT 

Thoratec Corp:Announced that its CE Mark Clinical Trial for HeartMate PHPTM (Percutaneous Heart Pump) has commenced.HeartMate PHP is a percutaneous device designed to deliver short-term support for patients needing acute cardiac assistance.  Full Article

Thoratec Corp acquires Apica Cardiovascular
Wednesday, 2 Jul 2014 04:15pm EDT 

Thoratec Corp:Acquires Apica Cardiovascular Limited (Apica) for upfront cash payment of $35 mln and potential future clinical and sales milestones of up to $40 mln.As part of agreement, Apica team based at facilities in Ireland and United States will transition to Thoratec.Thoratec will immediately assume ongoing development and commercialization of Apica VAD SIS and ASC platforms.  Full Article

Thoratec Corp reaffirms FY 2014 guidance
Tuesday, 6 May 2014 04:02pm EDT 

Thoratec Corp:Reiterates FY 2014 guidance for revenue of $520 million to $535 million and net income per diluted share of $1.28-1.38 on a GAAP basis and $1.72-1.82 on a non-GAAP basis.FY 2014 revenue of $527 million and EPS of $1.75 - Thomson Reuters I/B/E/S.  Full Article

Pomerantz LLP files class action against Thoratec Corporation and certain officers
Friday, 21 Feb 2014 03:28pm EST 

Pomerantz LLP:Filed a class action lawsuit against Thoratec Corporation and certain of its officers.The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects.Specifically, Defendants failed to disclose that the Company's HeartMate II Left Ventricular Assist Device had significant risk of pump thrombosis, causing numerous fatalities.  Full Article

Thoratec Corp gives FY 2014 guidance below analysts' estimates
Tuesday, 4 Feb 2014 04:02pm EST 

Thoratec Corp:Establishes FY 2014 guidance for revenue of $520 million to $535 million and net income per diluted share of $1.28-1.38 on a GAAP basis and $1.72-1.82 on a non-GAAP basis.FY 2014 revenue of $536 million and EPS of $1.86 - Thomson Reuters I/B/E/S.  Full Article

Glancy Binkow & Goldberg LLP files class action lawsuit against Thoratec Corporation
Tuesday, 4 Feb 2014 08:04am EST 

Glancy Binkow & Goldberg LLP:It has filed a class action lawsuit in the United States District Court for the Northern District of California on behalf of a class comprising all purchasers of Thoratec securities between Apr. 29, 2010 and Nov. 27, 2013.Says the complaint alleges that, throughout the Class Period, defendants failed to disclose that the company's HeartMate II Left Ventricular Assist Device had risk of pump thrombosis, causing numerous fatalities.  Full Article

Thoratec Corp announces fraud class action complaint in the U.S. District Court
Tuesday, 28 Jan 2014 08:00pm EST 

Thoratec Corp:Says Robbins Arroyo LLP announces that an investor of the company has filed a federal securities fraud class action complaint in the U.S. District Court for the Northern District of California.Says the complaint alleges that the company and certain of its officers violated the Securities and Exchange Act of 1934 between Apr. 29, 2010 and Nov. 27, 2013.  Full Article

Search Stocks